Malignant pleural mesothelioma: Clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features: Original Article

Pathology International

Volumn 59, Issue 8, 2009, Pages 537-545

  Hiroshima, Kenzo ^a   Yusa, Toshikazu ^a   Kameya, Toru ^b   Ito, Ichiro ^b   Kaneko, Kou ^c   Kadoyama, Chikabumi ^d   Kishi, Hirohisa ^c   Saitoh, Yukio ^e   Ozaki, Daisuke ^b   Itami, Makiko ^b   Iwata, Takekazu ^f   Iyoda, Akira ^g   Kawai, Toshiaki ^h   Yoshino, Ichiro ^a   Nakatani, Yukio ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Department of Pathology   (Japan)

^c Department of Pathology ^*  (Japan)

^d SAITAMA RED CROSS HOSPITAL   (Japan)

^e NARITA RED CROSS HOSPITAL   (Japan)

^f SAKURA NATIONAL HOSPITAL   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Early stage; Epithelial membrane antigen; GLUT 1; Immunohistochemistry; International Mesothelioma Interest Group; Mesothelioma; Mesothelioma in situ; Neoplasm staging; Pleura; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; GLUCOSE TRANSPORTER 1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FOCAL ADHESION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG RESECTION; MALE; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; SARCOMA; SARCOMATOID MESOTHELIOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ASBESTOS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY;

EID: 68249144983     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02404.x     Document Type: Article

References (29)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005 353 : 1591 603.
2. Hillerdal G. Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 1983 77 : 321 43.
3. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989 7 : 1157 68.
4. Neumann V, Gunthe S, Mulle KM, Fischer M. Malignant mesothelioma: German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001 74 : 383 95.
5. Sugarbaker DJ, Mentzer SJ, DeCamp M, Lynch TJ Jr., Strauss GM. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 1993 103 : 377S 381S.
6. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999 117 : 54 63, discussion 63-5.
7. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995 108 : 1122 8.
8. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumour. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC Press, 2004.
9. Gallagher B, Urbanski SJ. The significance of pleural elastica invasion by lung carcinomas. Hum Pathol 1990 21 : 512 17.
10. Flieder DB. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med 2007 131 : 1016 26.
11. Jones JS. The pleura in health and disease. Lung 2001 179 : 397 413.
12. Galateau-Salle F. Pathology of Malignant Mesothelioma. London : Springer, 2006.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc 1958 53 : 457 81.
14. Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000 24 : 1183 200.
15. Heelan R. Staging and response to therapy of malignant pleural mesothelioma. Lung Cancer 2004 45 (Suppl 1 S59 61.
16. Van Schil P. Malignant pleural mesothelioma: Staging systems. Lung Cancer 2005 49 (Suppl 1 S45 8.
17. Erasmus JJ, Truong MT, Smythe WR et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 2005 129 : 1364 70.
18. Castagneto B, Zai S, Mutti L et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 2001 31 : 303 10.
19. Monnet I, Breau JL, Moro D et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: A phase II study. Chest 2002 121 : 1921 7.
20. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999 68 : 1799 804.
21. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging. AJR Am J Roentgenol 1999 172 : 1039 47.
22. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: Implications for diagnosis and histogenesis. Semin Diagn Pathol 1992 9 : 151 61.
23. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993 72 : 394 404. (Pubitemid 23193444)
24. Davis JM. Histogenesis and fine structure of peritoneal tumors produced in animals by injections of asbestos. J Natl Cancer Inst 1974 52 : 1823 37.
25. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003 43 : 231 8.
26. Kato Y, Tsuta K, Seki K et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007 20 : 215 20.
27. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: A brief review. Am J Clin Pathol 1998 110 : 397 404.
28. Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001 122 : 788 95.
29. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg 2008 135 : 620 6, 626e1 3.